Richter-like transformation of CLL/SLL after a temporary hold of ibrutinib: A case report.
증례보고
1/5 보강
Bruton tyrosine kinase (BTK) inhibitors are used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), providing survival benefits over traditional chemoimmunotherapy.
APA
Chiang TL, Frater J, Cashen A (2026). Richter-like transformation of CLL/SLL after a temporary hold of ibrutinib: A case report.. Leukemia research reports, 25, 100578. https://doi.org/10.1016/j.lrr.2026.100578
MLA
Chiang TL, et al.. "Richter-like transformation of CLL/SLL after a temporary hold of ibrutinib: A case report.." Leukemia research reports, vol. 25, 2026, pp. 100578.
PMID
41815775 ↗
Abstract 한글 요약
Bruton tyrosine kinase (BTK) inhibitors are used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), providing survival benefits over traditional chemoimmunotherapy. Richter transformation is the transformation of CLL/SLL into an aggressive lymphoma, typically necessitating an immediate start of treatment. This case report presents a CLL/SLL patient developing pathology-proven Richter transformation after a short hold of the BTK inhibitor, without clinical evidence of disease progression. This case also demonstrates that the pathology-only Richter transformation after a pause of the BTK inhibitor can respond to resumption of the inhibitor, without the addition of intensive chemotherapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Comparative evaluation of two NGS-based assays for somatic hypermutation analysis of IGHV genes in chronic lymphocytic leukemia.
- Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy.
- From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management.
- Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis.
- Longitudinal Whole-Exome Sequencing Identifies Clonal Hematopoiesis and Genomic Heterogeneity as a Predictor of Treatment Outcome in Patients with Newly Diagnosed, Elderly Chronic Lymphocytic Leukemia.
- Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies.